Starling Oncology (STLN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$587.2M

Revenue (quarter)

$161.3M

Revenue growth (year over year)

+34.62%

Gross profit (trailing twelve months)

$92.2M

Gross margin

15.69%

Net income (trailing twelve months)

−$36.3M

Net income (quarter)

−$9.8M

Net income growth (year over year)

+42.45%

Net margin

−6.18%

Return on equity

—

EPS (trailing twelve months)

−$0.29

Book value per share

−$0.25

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

113.98%

Payout ratio

—

Dividend yield

—

Company profile

Starling Oncology Inc provides oncology care services in community settings. Its services include cancer diagnosis and treatment, clinical trials, transfusion services, and other oncology care delivery models for patients.

• Is Starling Oncology (STLN) profitable?

  No. Starling Oncology reported a net loss of $36.3M over the trailing twelve months.

• How much revenue does Starling Oncology (STLN) make?

  Starling Oncology generated $587.2M in revenue over the trailing twelve months, up 34.62% year over year.

• How do I buy stock in Starling Oncology (STLN)?

  STLN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.